164 related articles for article (PubMed ID: 11369844)
21. Pathophysiology of cardiovascular damage in the early renal population.
London G
Nephrol Dial Transplant; 2001; 16 Suppl 2():3-6. PubMed ID: 11369841
[TBL] [Abstract][Full Text] [Related]
22. Hemoglobin levels, cardiovascular disease, and left ventricular hypertrophy in patients with chronic kidney disease. Case study of the anemic patient.
Butler KG
Nephrol Nurs J; 2002 Apr; 29(2):189-92. PubMed ID: 11997954
[TBL] [Abstract][Full Text] [Related]
23. Cardiovascular mortality in haemodialysis patients treated with epoetin beta - a retrospective study.
Möcks J
Nephron; 2000 Dec; 86(4):455-62. PubMed ID: 11124594
[TBL] [Abstract][Full Text] [Related]
24. Pathophysiology of anaemia: focus on the heart and blood vessels.
Metivier F; Marchais SJ; Guerin AP; Pannier B; London GM
Nephrol Dial Transplant; 2000; 15 Suppl 3():14-8. PubMed ID: 11032352
[TBL] [Abstract][Full Text] [Related]
25. [Erythropoietin-beta in the treatment of anemia in patients with chronic renal insufficiency].
Dimković N
Med Pregl; 2001; 54(5-6):235-40. PubMed ID: 11759218
[TBL] [Abstract][Full Text] [Related]
26. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update.
Bokemeyer C; Aapro MS; Courdi A; Foubert J; Link H; Osterborg A; Repetto L; Soubeyran P;
Eur J Cancer; 2007 Jan; 43(2):258-70. PubMed ID: 17182241
[TBL] [Abstract][Full Text] [Related]
27. A prospective multicentre study of the role of anaemia as a risk factor in haemodialysis patients: the MAR Study.
Portolés J; López-Gómez JM; Aljama P
Nephrol Dial Transplant; 2007 Feb; 22(2):500-7. PubMed ID: 17023492
[TBL] [Abstract][Full Text] [Related]
28. Effect of anemia correction on left ventricular hypertrophy in patients with modestly high hemoglobin level and chronic kidney disease .
Akaishi M; Hiroe M; Hada Y; Suzuki M; Tsubakihara Y; Akizawa T;
J Cardiol; 2013 Oct; 62(4):249-56. PubMed ID: 23787155
[TBL] [Abstract][Full Text] [Related]
29. Short term correction of anaemia with recombinant human erythropoietin and reduction of cardiac output in end stage renal failure.
Morris KP; Skinner JR; Hunter S; Coulthard MG
Arch Dis Child; 1993 May; 68(5):644-8. PubMed ID: 8323333
[TBL] [Abstract][Full Text] [Related]
30. [Diastolic dysfunction in different types of left ventricular hypertrophy in patients with end-stage renal failure: impact of long-term erythropoietin therapy].
Dzgoeva FU; Gatagonova TM; Kadzaeva ZK; Khamitsaeva OV; Kochisova ZKh; Dzueva AT; Bazaeva BG; Bestaeva TL
Ter Arkh; 2013; 85(6):44-50. PubMed ID: 23866598
[TBL] [Abstract][Full Text] [Related]
31. [Frequency of anaemia and indications for treatment with epoetin in chronic renal failure at the pre-dialysis stage].
Jungers PY; Nguyen-Khoa T; Joly D; Choukroun G; Massy ZA; Jungers P
Presse Med; 2003 Feb; 32(5):212-6. PubMed ID: 12610461
[TBL] [Abstract][Full Text] [Related]
32. Effects of erythropoietin on left ventricular hypertrophy in adults with severe chronic renal failure and hemoglobin <10 g/dL.
Ayus JC; Go AS; Valderrabano F; Verde E; de Vinuesa SG; Achinger SG; Lorenzo V; Arieff AI; Luño J;
Kidney Int; 2005 Aug; 68(2):788-95. PubMed ID: 16014057
[TBL] [Abstract][Full Text] [Related]
33. Epoetin alfa's effect on left ventricular hypertrophy and subsequent mortality.
Jones M; Schenkel B; Just J
Int J Cardiol; 2005 Apr; 100(2):253-65. PubMed ID: 15823633
[TBL] [Abstract][Full Text] [Related]
34. Individualizing target haemoglobin concentrations--tailoring treatment for renal anaemia.
Macdougall IC
Nephrol Dial Transplant; 2001; 16 Suppl 7():9-14. PubMed ID: 11590250
[TBL] [Abstract][Full Text] [Related]
35. Guidelines and recommendations for the management of anaemia in patients with lymphoid malignancies.
Henry DH
Drugs; 2007; 67(2):175-94. PubMed ID: 17284083
[TBL] [Abstract][Full Text] [Related]
36. [Guidelines for the treatment of anemia in chronic renal failure].
Triolo G;
G Ital Nefrol; 2003; 20 Suppl 24():S61-82. PubMed ID: 14666504
[TBL] [Abstract][Full Text] [Related]
37. Is early treatment of anaemia with epoetin-alpha beneficial to pre-dialysis chronic kidney disease patients? Results of a multicentre, open-label, prospective, randomized, comparative group trial.
Macdougall IC; Temple RM; Kwan JT
Nephrol Dial Transplant; 2007 Mar; 22(3):784-93. PubMed ID: 16968726
[TBL] [Abstract][Full Text] [Related]
38. The effects of maintenance recombinant human erythropoietin therapy on ambulatory blood pressure recordings: conventional, Doppler, and tissue Doppler echocardiographic parameters.
Kirkpantur A; Kahraman S; Yilmaz R; Arici M; Altun B; Erdem Y; Yasavul U; Turgan C
Artif Organs; 2005 Dec; 29(12):965-72. PubMed ID: 16305652
[TBL] [Abstract][Full Text] [Related]
39. Epoetin beta (NeoRecormon) corrects anaemia in patients with hormone-refractory prostate cancer and bone metastases.
Bogdanos J; Karamanolakis D; Milathianakis K; Repousis P; Chloraki-Bobota A; Majed H; Pagalou-Thoua E; Tsintavis A; Koutsilieris M
Anticancer Res; 2004; 24(3b):1957-61. PubMed ID: 15274384
[TBL] [Abstract][Full Text] [Related]
40. Proven strategies to reduce cardiovascular mortality in hemodialysis patients.
Hampl H; Hennig L; Rosenberger C; Gogoll L; Riedel E; Scherhag A
Blood Purif; 2006; 24(1):100-6. PubMed ID: 16361849
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
